Latest Internal Medicine News

Avinash Ketwaroo, MD, MSc, associate professor of medicine (digestive diseases), discusses the symptoms of norovirus.

A recent study found new ways to identify mismatches between donors and recipients in kidney transplantation.

The National Institutes of Health (NIH) and the U.S. Food and Drug Administration (FDA) have renewed a $20 million grant for the Yale Tobacco Center of Regulatory Science (TCORS). The Yale center is led by co-directors Suchitra Krishnan-Sarin, PhD, Albert E. Kent Professor of Psychiatry; and Stephanie O’Malley, PhD, Elizabeth Mears and House Jameson Professor of Psychiatry.

Identifying innovative solutions to improve the health of people impacted by incarceration is part of the mission of Yale’s SEICHE Center for Health and Justice. On Monday, September 25, the Center announced its latest initiative to assist this historically underserved population, new programs to educate correctional health care workers on providing care for both non-communicable diseases such as high blood pressure or diabetes, and infectious diseases like hepatitis C.

A new study published in Annals of Family Medicine explores encounters between 30 transgender people and their health care clinicians.

Ash Alpert, MD, instructor of medicine (hematology), led a study that showed transgender people struggle to get adequate healthcare due to stigma and other issues.

A recent Yale study found that a newly developed drug could show promise in slowing the progression of non-small cell lung cancer in patients for whom previous treatments had not been effective. Presented at the World Conference on Lung Cancer in Singapore in September, the study found that an immunotherapy medication called NC318 could increase the effectiveness of existing cancer treatments and provide an alternative treatment for patients who did not respond to prior immunotherapy. “In the end, we saw 28% of our patients who had, what we felt, was benefit from this therapy,” said Scott Gettinger, Chief of Thoracic Oncology at the Yale Cancer Center and the study’s lead author. “Which is promising, considering we don’t have anything else. If what we see early on pans out, then this offers a potential salvage therapy for patients who progressed after chemotherapy and immunotherapy, which is the majority of our patients.”

Fall is upon us and that means students are back to school! We welcome the arrival of the new Yale School of Medicine Class of 2027 who will also be the first matriculated class of students to each be assigned a longitudinal coach!

Meet Mary Thomas, MD, MPH, clinical fellow in Yale Geriatrics, who hopes to make an impact on the care that underserved and vulnerable populations receive.